Share This Page
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Neomycin And Polymyxin B Sulfates And Gramicidin, and when can generic versions of Neomycin And Polymyxin B Sulfates And Gramicidin launch?
Neomycin And Polymyxin B Sulfates And Gramicidin is a drug marketed by Bausch And Lomb Inc, Ipharm, Sciegen Pharms, and Watson Labs. and is included in four NDAs.
The generic ingredient in NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN is gramicidin; neomycin sulfate; polymyxin b sulfate. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the gramicidin; neomycin sulfate; polymyxin b sulfate profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN?
- What are the global sales for NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN?
- What is Average Wholesale Price for NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN?
Summary for NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN
| US Patents: | 0 |
| Applicants: | 4 |
| NDAs: | 4 |
| Finished Product Suppliers / Packagers: | 2 |
| DailyMed Link: | NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN at DailyMed |
US Patents and Regulatory Information for NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN
Neomycin, Polymyxin B and Gramicidin Market Dynamics, Patent Status and Financial Trajectory
Neomycin and polymyxin B sulfates and gramicidin is a mature ophthalmic antibiotic combination sold primarily as a generic prescription product. Its commercial profile is defined by low unit prices, multiple suppliers, limited differentiation, and recurring demand for treatment of susceptible superficial ocular infections. The product has no meaningful biosimilar exposure, and its principal risks are manufacturing compliance, supply continuity, generic price compression, and changing antibiotic-prescribing practices rather than patent litigation.
Product-specific revenue is generally not reported by public manufacturers. Financial performance must therefore be assessed through prescription volume, reimbursement, supplier participation, procurement contracts, manufacturing capacity, and the broader ophthalmic anti-infective market.
What is neomycin, polymyxin B and gramicidin used for?
The product is an ophthalmic antibacterial solution containing three active ingredients:
| Active ingredient | Pharmacologic role |
|---|---|
| Neomycin sulfate | Aminoglycoside antibiotic that inhibits bacterial protein synthesis |
| Polymyxin B sulfate | Disrupts bacterial cell membranes, particularly in susceptible gram-negative organisms |
| Gramicidin | Disrupts bacterial membrane function, primarily against susceptible gram-positive organisms |
The combination is labeled for topical treatment of superficial infections of the eye and adnexa caused by susceptible organisms. It is not an antiviral, antifungal, or anti-inflammatory product. The prescribing information warns about hypersensitivity, including sensitization to neomycin, and the potential for bacterial overgrowth with prolonged use. [1]
The product is generally dispensed as an ophthalmic solution. It is distinct from combination products containing bacitracin, hydrocortisone, dexamethasone, or other corticosteroids.
What is the FDA regulatory status of neomycin, polymyxin B and gramicidin?
Neomycin, polymyxin B and gramicidin ophthalmic solution is an FDA-approved prescription ophthalmic anti-infective available through generic approval pathways. FDA-approved products in this category are typically marketed under the active-ingredient name rather than through a single dominant national brand.
The regulatory model is abbreviated new drug application, or ANDA, for products that reference an approved product and demonstrate pharmaceutical equivalence and bioequivalence where applicable. The product is not a biologic and does not require a biosimilar application under the Public Health Service Act.
Key FDA characteristics
| Regulatory element | Status |
|---|---|
| Dosage form | Ophthalmic solution |
| Route | Topical ocular |
| Prescription status | Prescription drug |
| Approval pathway for later entrants | ANDA or equivalent generic pathway |
| Biologic status | Not a biologic |
| Biosimilar pathway | Not applicable |
| Therapeutic category | Ophthalmic antibacterial |
| Orange Book relevance | Applicable to approved drug products and listed patents, if any |
| Main regulatory risks | Quality, sterility, labeling, manufacturing compliance and supply continuity |
FDA labeling identifies the product as a topical ophthalmic antibacterial combination. DailyMed carries manufacturer-specific labeling for products containing the same active ingredients and strength. [1,2]
What patents protect neomycin, polymyxin B and gramicidin?
The core active-ingredient combination is an old, off-patent product. No commercially important, product-wide composition-of-matter patent is expected to block generic competition.
The relevant intellectual-property position is best described as follows:
| Patent category | Commercial relevance |
|---|---|
| Core composition patent | Expired or no longer commercially blocking |
| Basic ophthalmic-solution patent | No meaningful exclusivity expected |
| Method-of-use patent | Limited practical value for standard labeled use |
| Formulation patent | Potentially relevant only if tied to a differentiated vehicle, preservative system, container or delivery method |
| Manufacturing patent | May protect a process but normally does not prevent equivalent generic products |
| Device patent | Could apply to a specialized dispenser, but not to the standard active-ingredient combination |
| Orange Book-listed patent risk | Low for the mature generic product |
FDA’s Orange Book identifies approved drug products and patent information submitted by applicants for listed products. Mature generic ophthalmic antibiotics often have no enforceable patent estate that materially controls market entry. [3]
A manufacturer could hold intellectual property covering a particular preservative system, container closure, manufacturing process, or packaging configuration. Those rights would not normally prevent another company from marketing a therapeutically equivalent formulation using a different process or package.
When does neomycin, polymyxin B and gramicidin lose exclusivity?
The product has already lost practical market exclusivity. Its commercial exclusivity ended after the expiration of any applicable historical patents and regulatory exclusivities associated with the original approved product.
Unlike a recently approved small-molecule drug, this product does not have a meaningful remaining exclusivity period that can support premium pricing. Generic manufacturers compete primarily on:
- Wholesale acquisition price
- Pharmacy reimbursement
- Contract pricing
- Product availability
- Manufacturing reliability
- Wholesaler distribution
- Regulatory inspection history
- Ability to maintain sterile ophthalmic production
No standard Hatch-Waxman exclusivity event, such as 180-day first-filer exclusivity, is central to the current market unless a specific ANDA applicant has obtained such status for a particular reference product. That determination must be made at the individual ANDA level through FDA records. [3,4]
How many patents cover neomycin, polymyxin B and gramicidin?
There is no commercially meaningful patent count that defines the product market in the way it would for a newly launched branded drug. Patent records may include historical compound, formulation, process, packaging, or use claims, but the existence of such records does not establish an active barrier to generic entry.
For market analysis, the relevant conclusion is:
- The active ingredients are established antibiotics.
- The standard combination is commercially generic.
- Any remaining patent rights would likely be narrow and product-specific.
- Generic entry is not dependent on a single surviving composition patent.
- Patent litigation is not the primary competitive variable.
USPTO records can include expired patents and patents assigned to predecessor companies. Those records should not be treated as active market exclusivity without confirmation of legal status, claim scope, and relevance to the marketed dosage form. [5]
What is the Orange Book status of neomycin, polymyxin B and gramicidin?
The product is subject to the FDA’s Orange Book framework because it is an approved prescription drug. The Orange Book can identify reference-listed drugs, therapeutic equivalence codes, and patents submitted by sponsors.
For a mature generic ophthalmic antibiotic, the commercial Orange Book issues are usually limited to:
- Whether a reference-listed drug remains actively marketed
- Whether an ANDA has a therapeutic-equivalence rating
- Whether any patent certification was required
- Whether a listed patent applies to the exact solution, strength, and route
- Whether an approved product has been discontinued or withdrawn for reasons other than safety or effectiveness
A generic product may remain commercially viable even when the original brand is discontinued, provided FDA has an approved reference product and the generic product satisfies applicable requirements. FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations is the controlling reference for Orange Book determinations. [3]
Are there Paragraph IV challenges for this product?
Paragraph IV litigation is not a major current market feature for the standard neomycin, polymyxin B and gramicidin ophthalmic solution.
A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. Such challenges are most commercially significant when a branded product has active Orange Book patents and high revenue exposure. This combination does not generally present that profile.
Potential Paragraph IV activity would be relevant only if:
- A sponsor listed an active patent for a specific formulation or delivery system.
- A new branded product obtained approval with differentiated claims.
- A generic applicant challenged a narrow device or formulation patent.
- A litigation settlement delayed or conditioned generic launch.
The absence of high-profile Paragraph IV litigation is consistent with the product’s age, low differentiation, and generic market structure. FDA’s Paragraph IV information should be reviewed at the specific product and ANDA level rather than inferred from the active ingredients alone. [4]
What formulations are protected by patents?
The standard product is an aqueous ophthalmic solution. Commercial differentiation may arise from the following attributes:
| Formulation or presentation | Potential commercial value |
|---|---|
| Preservative system | May affect tolerability and storage requirements |
| Preservative-free packaging | Could support use in selected patients but may increase packaging cost |
| Container-closure system | May reduce contamination risk or improve dispensing |
| Multidose bottle design | Can affect convenience, sterility and manufacturing cost |
| Unit-dose packaging | May improve portability and reduce preservative exposure |
| Viscosity modification | Could influence ocular residence time |
| Novel delivery device | May support limited differentiation |
| Storage-stable formulation | Can reduce distribution losses and improve procurement value |
These features can support product differentiation, but they do not automatically create enforceable market exclusivity. A formulation patent must be active, claim the marketed product, and survive validity and infringement analysis.
For the conventional generic solution, manufacturing and sterility controls are generally more important than formulation patents.
Which companies are competing in the market?
Competition is fragmented. Products may be supplied by generic ophthalmic manufacturers, specialty pharmaceutical companies, contract manufacturers, and distributors that market products under private-label or national-label arrangements.
The competitive set can include companies with broader ophthalmic portfolios, such as:
- Bausch + Lomb
- Sandoz
- Viatris
- Akorn-related product portfolios
- Perrigo
- Smaller FDA-approved ophthalmic generic manufacturers
- Contract development and manufacturing organizations
The exact supplier list changes as products are launched, discontinued, acquired, transferred, or placed on temporary shortage status. FDA’s Drugs@FDA and the NDC Directory are the appropriate sources for active manufacturer and product-package information. [6,7]
Market share should be measured at the NDC and package level because the same active-ingredient combination may be sold under multiple labelers, package sizes, or distributor arrangements.
What drives market demand?
Demand is tied to the volume of diagnosed superficial ocular bacterial infections and physician prescribing behavior. The product competes with:
- Tobramycin ophthalmic solution
- Erythromycin ophthalmic ointment
- Bacitracin-containing ophthalmic products
- Fluoroquinolone ophthalmic antibiotics
- Sulfacetamide ophthalmic products
- Other aminoglycoside or polymyxin combinations
The competitive position is limited by several factors:
- Physicians may prefer newer agents with broader contemporary prescribing familiarity.
- Aminoglycoside hypersensitivity can limit repeated use.
- Antibiotic stewardship may reduce empiric use.
- Ophthalmic preservatives can affect tolerability.
- Many uncomplicated ocular conditions are viral, allergic, or self-limited rather than bacterial.
- Payers and pharmacies frequently substitute among low-cost generic ophthalmic antibiotics.
Demand is therefore relatively stable but not strongly growth-oriented. Volume can rise during periods of increased outpatient eye-care utilization, but pricing typically remains constrained.
How strong is the patent estate?
The patent estate is weak as a commercial barrier and moderate only in the narrow sense that a supplier could hold process, packaging, or formulation rights.
| Patent-strength factor | Assessment |
|---|---|
| Composition-of-matter protection | Very weak or expired |
| Remaining exclusivity | Minimal |
| Formulation differentiation | Possible but narrow |
| Manufacturing barriers | Moderate because sterile ophthalmic production is technically demanding |
| Regulatory switching cost | Moderate |
| Generic entry barrier | Low to moderate |
| Litigation exposure | Low |
| Pricing power from IP | Negligible |
The most durable barrier is not patent protection. It is the ability to produce sterile ophthalmic products consistently, pass FDA inspection, maintain validated processes, and secure reliable supply of active ingredients and packaging components.
What generic entry risks exist?
Generic entry risk is already realized because the product is generic. The relevant issue is incremental competition from additional suppliers or re-entry by discontinued manufacturers.
New entrants can pressure prices by:
- Offering lower acquisition cost
- Seeking wholesaler contracts
- Competing for Medicaid and managed-care volume
- Using contract manufacturing
- Adding alternative package sizes
- Targeting pharmacy chains and institutional buyers
The principal countervailing risk is supply disruption. Ophthalmic products require sterile manufacturing, and a plant shutdown, warning letter, recall, or component shortage can remove multiple suppliers at once. In a concentrated manufacturing segment, a quality event can produce temporary price increases even when long-term pricing remains low.
What is the financial trajectory for the product?
A product-specific public revenue series is generally unavailable because manufacturers do not separately disclose sales for this mature generic combination. The expected financial trajectory is:
| Period | Financial pattern |
|---|---|
| Historical branded phase | Higher pricing and limited competition |
| Early generic phase | Rapid price erosion and volume transfer |
| Mature generic phase | Stable or declining revenue per unit |
| Supply-constrained periods | Temporary price and margin volatility |
| Long-term outlook | Low-growth, low-margin, volume-dependent market |
Revenue is likely to depend more on prescription volume and supplier participation than on price expansion. Gross margins can vary materially by manufacturer based on:
- Manufacturing scale
- Plant utilization
- Active-ingredient procurement
- Packaging cost
- Contract manufacturing terms
- Recall and remediation expense
- Wholesale discounts
- Government reimbursement
The product is unlikely to be a major revenue driver for a diversified pharmaceutical company unless the company has a large ophthalmic portfolio or sells the product through a high-volume institutional contract.
What licensing deals affect the market?
Licensing and supply transactions are more likely to involve commercial rights, private-label distribution, or contract manufacturing than innovative molecule licensing.
Relevant deal structures may include:
- ANDA acquisition or transfer
- Product rights licensing
- Exclusive distribution agreements
- Private-label supply
- Manufacturing and supply agreements
- Portfolio transactions involving multiple ophthalmic generics
These transactions can change the labeler or commercial owner without changing the underlying product’s clinical profile. FDA approval transfers and NDC ownership changes should be separated from true intellectual-property licensing. Public disclosure is inconsistent for small generic products, so no single transaction database captures the full commercial landscape.
What litigation affects neomycin, polymyxin B and gramicidin?
The product has low expected patent-litigation exposure. More relevant disputes would involve:
- Product liability claims
- Manufacturing defects
- Sterility failures
- Recalls
- False advertising
- Distribution contracts
- ANDA ownership or transfer
- Trademark disputes involving product names
A patent case would require a specific asserted patent and a marketed product accused of infringement. The active ingredients alone do not indicate current litigation.
How does this product compare with tobramycin and fluoroquinolone eye drops?
| Factor | Neomycin/polymyxin B/gramicidin | Tobramycin | Fluoroquinolone ophthalmics |
|---|---|---|---|
| Market maturity | Very mature generic | Mature generic | Mix of mature generic and branded products |
| Patent strength | Low | Low for basic products | Variable by product |
| Price power | Low | Low to moderate | Moderate for differentiated products |
| Prescribing position | Established, but limited by sensitivity concerns | Common generic alternative | Often used where broader coverage is desired |
| Manufacturing risk | Sterile ophthalmic production | Sterile ophthalmic production | Sterile ophthalmic production |
| Biosimilar risk | None | None | None |
| Growth outlook | Low | Low to moderate | More favorable for selected products |
| Litigation risk | Low | Low | Higher where branded formulations remain |
The combination remains commercially relevant as a low-cost option, but it lacks the market expansion characteristics of a newly differentiated ophthalmic therapy.
Key Takeaways
- Neomycin, polymyxin B and gramicidin ophthalmic solution is a mature generic prescription antibiotic.
- The core active-ingredient combination has no meaningful remaining composition-patent barrier.
- Orange Book and Paragraph IV issues are product- and ANDA-specific but are not central market drivers.
- Biosimilar competition does not apply because the product is a conventional small-molecule drug.
- The main competitive variables are price, supply reliability, sterile manufacturing capacity, and payer access.
- Product-specific revenue is generally not publicly disclosed.
- Long-term financial performance is likely to be stable to declining on a per-unit basis, with temporary volatility during shortages or manufacturing disruptions.
- Formulation, packaging, and delivery patents may exist but are unlikely to create broad market exclusivity.
- Generic launch risk is already embedded in the market, while supply interruption is the more material near-term commercial risk.
FAQs
Is neomycin, polymyxin B and gramicidin still commercially available?
Yes. FDA-approved products containing the combination have been marketed as prescription ophthalmic solutions, although availability can vary by manufacturer, package size, wholesaler inventory, and product status.
Does this ophthalmic antibiotic have a branded reference product?
The market has included branded and generic presentations over time. Current commercial availability should be evaluated through Drugs@FDA, the Orange Book, and the NDC Directory rather than by relying on historical brand names.
Can a new company obtain FDA approval for this product?
Yes. A company may pursue an ANDA or another applicable abbreviated pathway if it can demonstrate pharmaceutical equivalence, bioequivalence where required, manufacturing compliance, and appropriate quality controls.
Are neomycin allergy concerns a major commercial limitation?
They can be. Neomycin sensitization is a recognized labeling concern and may influence physician selection, particularly for patients with prior exposure or suspected hypersensitivity.
Is the product attractive for pharmaceutical licensing?
It is generally more attractive as part of a broader ophthalmic generic portfolio than as a standalone licensing asset. Commercial value depends on manufacturing access, supply reliability, customer contracts, and portfolio scale rather than patent exclusivity.
References
-
DailyMed. (n.d.). Neomycin and polymyxin B sulfates and gramicidin ophthalmic solution prescribing information. U.S. National Library of Medicine.
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
U.S. Food and Drug Administration. (n.d.). Paragraph IV drug product and patent information. https://www.fda.gov/drugs
-
United States Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov/
-
U.S. Food and Drug Administration. (n.d.). National Drug Code Directory. https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory
-
U.S. Food and Drug Administration. (n.d.). Drug shortages. https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages
More… ↓
